Acadia Pharmaceuticals’ Nuplazid (pimavanserin) — which is being evaluated as a potential treatment for hallucinations and delusions associated with dementia-related psychosis — is not associated with common motor side effects of conventional antipsychotics, according to an analysis of data from three clinical trials. These findings add to previous…
Alzheimer’s disease is not often seen among those younger than 65, but the Youth Movement Against Alzheimer’s is getting young people involved with the neurological disorder through volunteer work, education, and advocacy. While they aren’t typically affected themselves,…
A new Phase 3 clinical trial, called EMBARK, will evaluate the long-term safety and efficacy of aducanumab (BIIB037), an investigational therapy for Alzheimer’s disease in patients who took part in its previous clinical studies. The trial’s design was described by Carmen Castrillo-Viguera, a medical director at Biogen, in the poster “…
Eisai and Biogen’s experimental therapy lecanemab (BAN2401) safely leads to rapid and sustained reductions in the brain levels of beta-amyloid — the protein that forms toxic clumps in Alzheimer’s — in people in early disease stages, according to one-year, preliminary data from a Phase 2 trial’s…
Despite minor improvements in recent years, the availability of care for people with dementia in Europe is largely inadequate, according to a new report. The report, “Dementia Monitor 2020,” was published by Alzheimer Europe, an organization that campaigns to ensure that Alzheimer’s disease and dementia are treated…
Following a positive review of preliminary data, an independent board recommended the Phase 2b/3 study investigating oral Anavex 2-73 (blarcamesine) in people with early Alzheimer’s disease continue without modification. As specified in trial protocol, the Independent Data Safety Monitoring Board (DSMB)…
Six months of treatment with GemVax & KAEL’s investigational GV1001 provided benefits in the cognition and daily life activities of adults with moderate to severe Alzheimer’s disease, who take Aricept (donepezil) for dementia, according to data from a Phase 2 clinical trial. The results were published…
Zahra Kababian had a special bond with her father, and even though he died suddenly 10 years ago, it’s the memories they shared that keeps him alive in her heart. It was those memories and his diagnosis of Alzheimer’s disease…
The U.S. Food and Drug Administration (FDA) has rejected Acadia Pharmaceuticals’ request that Nuplazid (pimavanserin) be the first approved treatment of hallucinations and delusions associated with dementia-related psychosis. The decision comes less than nine months since the agency agreed to review the company’s supplemental new drug application, and a month…
Montana residents who wish to help their children or young relatives better understand Alzheimer’s disease can now access a free storybook and reading guide. The reading guide, offered by the Montana State University (MSU) Extension program, includes questions to spark discussions about the storybooks and children’s activities. It…
Get regular updates to your inbox.